Cook TAA graft trial
This article was originally published in The Gray Sheet
Executive Summary
Firm completes enrollment for its STARZ-TX2 clinical trial comparing the Zenith TX2 endovascular graft to open surgery in the treatment of thoracic aortic aneurysms. The 200-patient trial, conducted at 39 sites, will evaluate patient survival and rupture rates over 12 months. WL Gore (Gore TAG) was first-to-market in the TAA endograft space in March 2005, with Medtronic (Talent) aiming to be next (1"The Gray Sheet" March 28, 2005, p. 13). Medtronic completed enrollment of its VALOR pivotal trial for Talent in June 2005...
You may also be interested in...
Medtronic’s Valiant thoracic aneurysm stent graft
Firm begins two clinical trials of its Valiant second-generation thoracic aortic aneurysm stent graft. Announced Dec. 15, the 125-patient Valor II U.S. trial will evaluate Valiant to treat descending thoracic aortic aneurysms. The firm also has initiated a 100-patient Virtue registry study in Europe to collect extra data on treatment of descending thoracic aortic dissections. Medtronic plans a U.S. marketing submission in two years. CE marked in 2005, Valiant is the leading thoracic aortic aneurysm endograft outside the United States, the firm says. Medtronic also offers its Talent thoracic stent graft outside the United States and hopes to gain FDA approval soon. Competitors include Cook (Zenith TX2) and Gore (TAG); the latter device is approved by FDA (1"The Gray Sheet" Aug. 7, 2006, In Brief)...
TAG Thoracic Endograft Approval Makes Gore First To Market In U.S.
Gore is negotiating with FDA the number of participants required for a post-approval study of TAG endoprosthesis to treat thoracic aortic aneurysms
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.